PHARMACOGENOMICS HYPERTENSION :A NEW APPROACH FOR PERSONALIZED MEDICINE ( PGX - HT ) - PGX-HT

OSPEDALE SAN RAFFAELE0 sitesSeptember 30, 2016

Overview

No summary available.

Registry

who.int

Start Date

September 30, 2016

End Date

TBD

Last Updated

9 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

OSPEDALE SAN RAFFAELE

•Patients aged between 25 and 60 years with newly diagnosed mild to moderate essential hypertension ( systolic blood pressure between 140 and 160 mmHg and diastolic blood pressure between 90 and 110 mmHg measured as the average of three consecutive measurements )
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 300
•F.1\.3 Elderly (\>\=65 years) no
•F.1\.3\.1 Number of subjects for this age range

•Known causes of secondary hypertension ;
•\- Pregnant women , nursing mothers or women of childbearing age taking anti \- contraceptives ;
•\- Severe hypertension or malignant ;
•\- History of kidney disease ;
•\- Significant renal disease ( creatinine clearance less than 60 ml / min ) ; anuria .
•\- Hypokalemia or hyponatremia refractory ;
•\- Hypercalcemia ;
•\-iperuricemia symptomatic ;
•\- Liver disease ;
•\- Heart disease ( myocardial infarction , atrial fibrillation , etc. ) ;